Identification of GP38 and NP antibodies that protect against CCHFV
Official title: Identification of GP38 and NP antibodies and their protective mechanisms against CCHFV
Funded at University of California Riverside · NIH-11404999 · Data updated 2026-11-12
A study to understand how specific antibodies can protect people from Crimean-Congo hemorrhagic fever virus and how these antibodies work.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Riverside NIH-funded |
| Lab location | 1 site (Riverside, United States) |
| Project start | September 3, 2025 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $689,335 |
| NIH project number | 5R01AI187352-02 |
| Project ID | NIH-11404999 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable for this grant (preclinical animal studies).
✕Less likely to help
No direct patient participation in this stage.
What this research studies
Researchers will study how antibodies against the GP38 protein of CCHFV help protect against infection, using animal models. The project will analyze how antibody binding and affinity relate to protection and characterize which antibody features are most protective. Findings could guide future vaccines or antibody-based therapies for people at risk of CCHFV exposure.
Why it matters
Potential benefit: This work could lead to better vaccines or antibody therapies to prevent or lessen CCHFV infections in people.
How similar studies have gone: Prior work has shown that GP38-targeting approaches can confer protection in models, supporting the potential of this strategy.
Where this research is happening
-
University of California Riverside
Riverside, United States Active
Researchers
- Principal investigator: Pegan, Scott Dusan — University of California Riverside
- Study coordinator: Pegan, Scott Dusan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.